Wednesday, December 08, 2021


Cuba’s Abdala vaccine candidate hits 40 million doses

Cuba’s Abdala vaccine candidate hits 40 million doses

Havana, Oct 27 (Latin Press) Cuba has been able to produce 40 million Abdala vaccine doses, a figure described as a milestone for the Cuban science, the CIGB reported Wednesday.
Share on facebook
Share on twitter
Share on whatsapp
Share on telegram
Share on email

On Twitter, the Center for Genetic Engineering and Biotechnology (CIGB) said that thanks to the go-getting decision to join efforts and resources with the Food Information and Control Agency (AICA), the Abdala candidate was guaranteed for the Cuban people and from other nations that may need it.

Abdala, the first vaccine candidate in Cuba and Latin America, showed a 90% effectiveness in critically-ill patients and against the Delta variant, as well as a 92,28% efficacy against symptomatic disease with.

The Abadala doses produced were destined to vaccine the Cuban people over 19, which includes pregnant women, nursing mothers, people with transplants, adolescents and young people in terminal grades of the national education system.


name of Prensa Latina

| Text SMS to 8100 with content PL
Receive 4 mesages x 25 cup

© 2016-2021 Prensa Latina
Latin American News Agency

Radio – Publications  – Videos – News by the minute.
All Rigts Reserved.

St. E No 454 , Vedado,  Habana, Cuba.
Phones: (+53) 7 838 3496, (+53) 7 838 3497, (+53) 7 838 3498, (+53) 7 838 3499
Prensa Latina © 2021 .

Web Site developed by IT Division  Prensa Latina.